209 related articles for article (PubMed ID: 33648535)
21. Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program.
Attiyeh EF; Maris JM; Lock R; Reynolds CP; Kang MH; Carol H; Gorlick R; Kolb EA; Keir ST; Wu J; Landesman Y; Shacham S; Lyalin D; Kurmasheva RT; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2016 Feb; 63(2):276-86. PubMed ID: 26398108
[TBL] [Abstract][Full Text] [Related]
22. XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.
Turner JG; Kashyap T; Dawson JL; Gomez J; Bauer AA; Grant S; Dai Y; Shain KH; Meads M; Landesman Y; Sullivan DM
Oncotarget; 2016 Nov; 7(48):78896-78909. PubMed ID: 27806331
[TBL] [Abstract][Full Text] [Related]
23. Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma.
Green AL; Ramkissoon SH; McCauley D; Jones K; Perry JA; Hsu JH; Ramkissoon LA; Maire CL; Hubbell-Engler B; Knoff DS; Shacham S; Ligon KL; Kung AL
Neuro Oncol; 2015 May; 17(5):697-707. PubMed ID: 25366336
[TBL] [Abstract][Full Text] [Related]
24. A method for quantification of exportin-1 (XPO1) occupancy by Selective Inhibitor of Nuclear Export (SINE) compounds.
Crochiere ML; Baloglu E; Klebanov B; Donovan S; Del Alamo D; Lee M; Kauffman M; Shacham S; Landesman Y
Oncotarget; 2016 Jan; 7(2):1863-77. PubMed ID: 26654943
[TBL] [Abstract][Full Text] [Related]
25. Differential diagnosis of atypical lipomatous tumor/well-differentiated liposarcoma and dedifferentiated liposarcoma: utility of p16 in combination with MDM2 and CDK4 immunohistochemistry.
Kammerer-Jacquet SF; Thierry S; Cabillic F; Lannes M; Burtin F; Henno S; Dugay F; Bouzillé G; Rioux-Leclercq N; Belaud-Rotureau MA; Stock N
Hum Pathol; 2017 Jan; 59():34-40. PubMed ID: 27597521
[TBL] [Abstract][Full Text] [Related]
26. HDACi inhibits liposarcoma via targeting of the MDM2-p53 signaling axis and PTEN, irrespective of p53 mutational status.
Ou WB; Zhu J; Eilers G; Li X; Kuang Y; Liu L; Mariño-Enríquez A; Yan Z; Li H; Meng F; Zhou H; Sheng Q; Fletcher JA
Oncotarget; 2015 Apr; 6(12):10510-20. PubMed ID: 25888633
[TBL] [Abstract][Full Text] [Related]
27. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors.
Turner JG; Dawson JL; Grant S; Shain KH; Dalton WS; Dai Y; Meads M; Baz R; Kauffman M; Shacham S; Sullivan DM
J Hematol Oncol; 2016 Aug; 9(1):73. PubMed ID: 27557643
[TBL] [Abstract][Full Text] [Related]
28. MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of action.
Somaiah N; Tap W
Cancer Treat Rev; 2024 Jan; 122():102668. PubMed ID: 38104352
[TBL] [Abstract][Full Text] [Related]
29. Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems.
Shang E; Zhang Y; Shu C; Ishida CT; Bianchetti E; Westhoff MA; Karpel-Massler G; Siegelin MD
Sci Rep; 2018 Oct; 8(1):15383. PubMed ID: 30337641
[TBL] [Abstract][Full Text] [Related]
30. Selinexor improves the anti-cancer effect of tucidinostat on TP53 wild-type breast cancer.
Shi Y; Xu S; Li S
Mol Cell Endocrinol; 2022 Apr; 545():111558. PubMed ID: 35033575
[TBL] [Abstract][Full Text] [Related]
31. Loss of p53 expression in cancer cells alters cell cycle response after inhibition of exportin-1 but does not prevent cell death.
Marcus JM; Burke RT; Doak AE; Park S; Orth JD
Cell Cycle; 2018; 17(11):1329-1344. PubMed ID: 30037299
[TBL] [Abstract][Full Text] [Related]
32. Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas.
Laroche-Clary A; Chaire V; Algeo MP; Derieppe MA; Loarer FL; Italiano A
J Hematol Oncol; 2017 Jun; 10(1):123. PubMed ID: 28629371
[TBL] [Abstract][Full Text] [Related]
33. Health-related quality of life and pain with selinexor in patients with advanced dedifferentiated liposarcoma.
Gounder M; Abdul Razak AR; Gilligan AM; Leong H; Ma X; Somaiah N; Chawla SP; Martin-Broto J; Grignani G; Schuetze SM; Vincenzi B; Wagner AJ; Chmielowski B; Jones RL; Shah J; Shacham S; Kauffman M; Riedel RF; Attia S
Future Oncol; 2021 Aug; 17(22):2923-2939. PubMed ID: 33855868
[TBL] [Abstract][Full Text] [Related]
34. FoxO-1 contributes to the efficacy of the combination of the XPO1 inhibitor selinexor and cisplatin in ovarian carcinoma preclinical models.
Corno C; Stucchi S; De Cesare M; Carenini N; Stamatakos S; Ciusani E; Minoli L; Scanziani E; Argueta C; Landesman Y; Zaffaroni N; Gatti L; Perego P
Biochem Pharmacol; 2018 Jan; 147():93-103. PubMed ID: 29155058
[TBL] [Abstract][Full Text] [Related]
35. Dedifferentiated liposarcoma and pleomorphic liposarcoma: a comparative study of cytomorphology and MDM2/CDK4 expression on fine-needle aspiration.
Mariño-Enríquez A; Hornick JL; Dal Cin P; Cibas ES; Qian X
Cancer Cytopathol; 2014 Feb; 122(2):128-37. PubMed ID: 24227706
[TBL] [Abstract][Full Text] [Related]
36.
Casadei L; Calore F; Braggio DA; Zewdu A; Deshmukh AA; Fadda P; Lopez G; Wabitsch M; Song C; Leight JL; Grignol VP; Lev D; Croce CM; Pollock RE
Cancer Res; 2019 Oct; 79(19):4911-4922. PubMed ID: 31387924
[TBL] [Abstract][Full Text] [Related]
37. Establishment and evaluation of retroperitoneal liposarcoma patient-derived xenograft models: an ideal model for preclinical study.
Xu C; Yan L; An Q; Zhang S; Guan X; Wang Z; Lv A; Liu D; Liu F; Dong B; Zhao M; Tian X; Hao C
Int J Med Sci; 2022; 19(8):1241-1253. PubMed ID: 35928724
[TBL] [Abstract][Full Text] [Related]
38. Co-expression of MDM2 and CDK4 in transformed human mesenchymal stem cells causes high-grade sarcoma with a dedifferentiated liposarcoma-like morphology.
Kim YJ; Kim M; Park HK; Yu DB; Jung K; Song K; Choi YL
Lab Invest; 2019 Sep; 99(9):1309-1320. PubMed ID: 31160689
[TBL] [Abstract][Full Text] [Related]
39. XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IκB.
Ming M; Wu W; Xie B; Sukhanova M; Wang W; Kadri S; Sharma S; Lee J; Shacham S; Landesman Y; Maltsev N; Lu P; Wang YL
Mol Cancer Ther; 2018 Dec; 17(12):2564-2574. PubMed ID: 30510142
[TBL] [Abstract][Full Text] [Related]
40. Targeting abundant survivin expression in liposarcoma: subtype dependent therapy responses to YM155 treatment.
Vay C; Schlünder PM; Dizdar L; Esposito I; Ghadimi MPH; Knoefel WT; Krieg A
J Cancer Res Clin Oncol; 2022 Mar; 148(3):633-645. PubMed ID: 34860309
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
